Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis: An experimental study

Cancer

Volumn 118, Issue 11, 2012, Pages 2986-2996

  Shao, Li Hua ^a   Liu, Shao Ping ^a   Hou, Jin Xuan ^a   Zhang, Yan Hua ^b   Peng, Chun Wei ^a   Zhong, Yan Jun ^a   Liu, Xiong ^a   Liu, Xiu Li ^a   Hong, Ya Ping ^c   Firestone, Raymond A ^d   Li, Yan ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b KUNMING MEDICAL UNIVERSITY   (China)

^c Princeton Global Synthesis LLC   (United States)

^d Apt 10A ^*  (United States)

Author keywords

cathepsin B; Doxorubicin; gastric cancer; peritoneal carcinomatosis; prodrug

Indexed keywords

ACETYLPHENYLALANYLLYSYL 4 AMINOBENZYLOXYCARBONYL DOXORUBICIN; ANTINEOPLASTIC AGENT; CATHEPSIN B; DOXORUBICIN; DOXORUBICIN DERIVATIVE; PRODRUG; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOMATOUS PERITONITIS; CARDIOTOXICITY; CELL CYCLE; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FUNCTION; LETHAL DOSE; LIVER FUNCTION; LIVER TOXICITY; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NEPHROTOXICITY; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RISK REDUCTION; STOMACH CANCER; TREATMENT OUTCOME;

ANIMALS; CARCINOMA; CATHEPSIN B; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; HEART; HUMANS; MALE; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; OLIGOPEPTIDES; PERITONEAL NEOPLASMS; PRODRUGS; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861330664     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26596     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006; 56: 106-130.
3. Bozzetti F, Yu W, Baratti D, Kusamura S, Deraco M,. Locoregional treatment of peritoneal carcinomatosis from gastric cancer. J Surg Oncol. 2008; 98: 273-276.
4. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001; 345: 725-730.
5. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355: 11-20.
6. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007; 357: 1810-1820.
7. Juhl H, Stritzel M, Wroblewski A, et al. Immunocytological detection of micrometastatic cells: comparative evaluation of findings in the peritoneal cavity and the bone marrow of gastric, colorectal and pancreatic cancer patients. Int J Cancer. 1994; 57: 330-335.
8. Yonemura Y, Endou Y, Shinbo M, et al. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: selection for cytoreductive surgery. J Surg Oncol. 2009; 100: 311-316.
9. Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011; 18: 1575-1581.
10. Dohchin A, Suzuki J, Seki H, Masutani M, Shiroto H, Kawakami Y,. Immunostained cathepsins B and L correlate with depth of invasion and different metastatic pathways in early stage gastric carcinoma. Cancer. 2000; 89: 482-487.
11. Ebert MP, Kruger S, Fogeron ML, et al. Overexpression of cathepsin B in gastric cancer identified by proteome analysis. Proteomics. 2005; 5: 1693-1704.
12. Sitabkhan Y, Frankfater A,. Differences in the expression of cathepsin B in B16 melanoma metastatic variants depend on transcription factor Sp1. DNA Cell Biol. 2007; 26: 673-682.
13. Eijan AM, Sandes EO, Riveros MD, et al. High expression of cathepsin B in transitional bladder carcinoma correlates with tumor invasion. Cancer. 2003; 98: 262-268.
14. Czyzewska J, Guzinska-Ustymowicz K, Kemona A, Bandurski R,. The expression of matrix metalloproteinase 9 and cathepsin B in gastric carcinoma is associated with lymph node metastasis, but not with postoperative survival. Folia Histochem Cytobiol. 2008; 46: 57-64.
15. Sevenich L, Schurigt U, Sachse K, et al. Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. Proc Natl Acad Sci U S A. 2010; 107: 2497-2502.
16. Nouh MA, Mohamed MM, El-Shinawi M, et al. Cathepsin B: a potential prognostic marker for inflammatory breast cancer. J Transl Med. 2011; 9: 1.
17. Atkinson JM, Siller CS, Gill JH,. Tumour endoproteases: the cutting edge of cancer drug delivery? Br J Pharmacol. 2008; 153: 1344-1352.
18. Dubowchik GM, Firestone RA,. Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. Bioorg Med Chem Lett. 1998; 8: 3341-3346.
19. Dubowchik GM, Mosure K, Knipe JO, Firestone RA,. Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. Bioorg Med Chem Lett. 1998; 8: 3347-3352.
20. Dubowchik GM, Firestone RA, Padilla L, et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem. 2002; 13: 855-869.
21. He W, Qin XJ, Hai CX, et al. Adriamycin's acute toxicity in mice through celiac injection and its effect on the peritoneal blood. J Fourth Mil Med Univ. 2002; 23: 667-669.
22. Kratz F, Ehling G, Kauffmann HM, Unger C,. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin. Hum Exp Toxicol. 2007; 26: 19-35.
23. Schmid B, Chung DE, Warnecke A, Fichtner I, Kratz F,. Albumin-binding prodrugs of camptothecin and doxorubicin with an ala-leu-ala-leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy. Bioconjug Chem. 2007; 18: 702-716.
24. Monneuse O, Mestrallet JP, Quash G, Gilly FN, Glehen O,. Intraperitoneal treatment with dimethylthioampal (DIMATE) combined with surgical debulking is effective for experimental peritoneal carcinomatosis in a rat model. J Gastrointest Surg. 2005; 9: 769-774.
25. Peng CW, Liu XL, Chen C, et al. Patterns of cancer invasion revealed by QDs-based quantitative multiplexed imaging of tumor microenvironment. Biomaterials. 2011; 32: 2907-2917.
26. Raue W, Kilian M, Braumann C, et al. Multimodal approach for treatment of peritoneal surface malignancies in a tumour-bearing rat model. Int J Colorectal Dis. 2010; 25: 245-250.
27. Sun P, Xiang JB, Chen ZY,. Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. Br J Surg. 2009; 96: 26-33.
28. Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010; 303: 1729-1737.
29. Chua YJ, Cunningham D,. The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice. Ann Surg Oncol. 2007; 14: 2687-2690.
30. D'Ugo D, Rausei S, Biondi A, Persiani R,. Preoperative treatment and surgery in gastric cancer: friends or foes? Lancet Oncol. 2009; 10: 191-195.
31. Rabbani A, Finn RM, Ausio J,. The anthracycline antibiotics: antitumor drugs that alter chromatin structure. Bioessays. 2005; 27: 50-56.
32. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376: 687-697.
33. Carl PL, Chakravarty PK, Katzenellenbogen JA,. A novel connector linkage applicable in prodrug design. J Med Chem. 1981; 24: 479-480.
34. Portilla AG, Sugarbaker PH, Chang D,. Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features. World J Surg. 1999; 23: 23-29.